Chiesi group Related News
Oak Hill Bio and Chiesi enrol first European patient in bronchopulmonary dysplasia treatment study
Oak Hill Bio and Chiesi Group have launched a groundbreaking study of a revolutionary bronchopulmonary dysplasia treatment for extremely premature infants.
Oak Hill Bio, a...
Chiesi NICU campaign and documentary to raise awareness for premature births
Premature births disrupt the expected narrative of a pregnancy, intertwining vulnerability with resilience.
In their campaign, Unscripted Beginnings. A Fragile Start, a Strong Future, Chiesi...
Chiesi places 23rd in 2024 World’s Best Workplaces™ List
This is the first time that Chiesi has been included in the GPTW global list, making it the first Italian company to achieve this honour.
Chiesi launches ‘The Impulse’ to drive innovation and collaboration in healthcare
The Impulse will tackle huge challenges facing patients and the planet by addressing symptoms and the root causes of these challenges.
Chiesi Group’s new Biotech Center of Excellence brings the future of medicine to Parma
Chiesi Group is making a strategic investment of € 400 million to establish its new Biotech Center of Excellence in Parma.
Chiesi Group, an international...
Laura Vergani joins Chiesi Group to lead global communications & public affairs
Laura Vergani has joined Chiesi Group this week as Senior Vice President of Global Communications & Public Affairs.
Chiesi Group releases 2023 sustainability report
Chiesi, an international biopharmaceutical group, has published its 2023 sustainability report. Find out more.